Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple steatosis, through to inflammation and fibrosis with a significant risk for the development of cirrhosis. It is highly prevalent and is associated with significant adverse outcomes both through liver-specific morbidity and mortality, but perhaps more importantly, through adverse cardiovascular and metabolic outcomes. It is tightly associated with type 2 diabetes and obesity and both of these conditions drive progressive disease towards the more advanced stages. The mechanisms that govern hepatic lipid accumulation and the predisposition to inflammation and fibrosis are still not fully understood, but reflect a complex interplay between metabolic target tissues including adipose and skeletal muscle, and immune and inflammatory cells.

Original publication

DOI

10.1210/endrev/bnz009

Type

Journal article

Journal

Endocrine reviews

Publication Date

20/10/2019

Addresses

Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, UK.